UMass’s Stacyann Bailey receives $400,000 from NCI to research whether checkpoint inhibitors worsen bone damage in metastatic cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stacyann Bailey, assistant professor of biomedical engineering at the University of Massachusetts Amherst, has received a two-year grant from NCI to study the complex relationship between drugs used to treat metastatic cancer and the development of bone damage.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Confidential Trump administration budget documents show that the upcoming FY26 Budget Request will radically cut about $50 billion out of the U.S. Department of Health and Human Services, reshuffling agency components, and slashing the number of NIH institutes and centers to just eight. 
Most cancer genome studies have focused on mutations in the tumor itself and how such gene variants allow a tumor to grow unchecked. A study led by researchers at Washington University School of Medicine in St. Louis takes a deep dive into inherited cancer mutations measured in a healthy blood sample and reports how those mutations might take a toll on the body’s cells starting at birth, perhaps predisposing a person to develop cancers at various stages of life.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login